Business
Waverley Pharma Announces Grant of Marketing Authorization in the United Kingdom for Erlotinib
Waverley Pharma Announces Grant of Marketing Authorization in the United Kingdom for Erlot...
About this update from Waverley Pharma, Inc.
[{"type":"text","content":"\n\n\n\nWaverley Pharma Announces Grant of Marketing Authorization in the United Kingdom for Erlotinib\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, Dec. 17, 2019\n\n\n\nWINNIPEG, Dec. 17, 2019 /CNW/ - Waverley Pharma Inc. (\"Waverley Pharma\" or the \"Company\") (TSXV:WAVE), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly-owned  Irish subsidiary, Waverley Pharma Europe Limited, has been granted marketing authorization in the United Kingdom by the Medicines & Healthcare products Regulatory Agency (MHRA) for three different strengths of generic Erlotinib (25 mg, 100 mg and 150 mg tablets).   Erlotinib is an oral oncology medication used to treat non-small cell lung cancer and pancreatic cancer.  \nAbout Waverley Pharma \nWaverley Pharma is an emerging pharmaceutical company focused on the development and commercialization of safe, effective and affordable cancer therapeutics in the EU and North American market. The Company, through its subsidiary, is selling two generic oncology products in the United Kingdom, namely capecitabine and temozolomide and has three additional generic products under development. Waverley Pharma is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. For more information on Waverley Pharma please visit www.waverleypharma.com. \nNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. \nForward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words \"believes\", \"may\", \"plans\", \"will\", \"estimates\", \"continues\", \"anticipates\", \"intends\", \"expects\" and similar expressions, may constitute \"forward-looking information\" within the meaning of applicable Canadian and U.S. federal securities laws (suc...